Chemotherapy-induced premature ovarian failure: Mechanisms and prevention

Steroids

Volumn 54, Issue 6, 1989, Pages 607-626

  Ataya, K ^a   Moghissi, K ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GOSERELIN;

ANIMAL EXPERIMENT; ARTICLE; GRANULOSA CELL; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; OOCYTE; OVARY; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMAL; CYCLOPHOSPHAMIDE; FEMALE; GRANULOSA CELLS; HUMAN; IN VITRO; MACACA MULATTA; MALE; OVARIAN DISEASES; RATS; RATS, INBRED STRAINS; RECEPTORS, LHRH; SUPPORT, NON-U.S. GOV'T;

ANIMALIA; PRIMATES; RATTUS;

EID: 0024819408     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0039-128X(89)90084-6     Document Type: Article

References (104)

1. Curability of advanced Hodgkin's disease with chemotherapy
2. Cancer statistics
3. Effect of cytotoxic therapy on sexuality and gonadal function
4. Cytotoxic induced ovarian failure in women with Hodgkin's disease. I. Hormone function
5. Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy of Hodgkin's disease
6. The relationship of gonadal activity and chemotherapy-induced gonadal damage
7. Ovarian failure following abdominal irradiation in childhood
8. Cyclophosphamide and cisdicholorodiamine platinum (11) nonempiric scheduling to spare dose-limiting tisues in the rat
9. A prevention of chemotherapy-induced ovarian follicular loss in rats
10. Effects of long-term estrogen replacement therapy
11. Premature ovarian failure
12. Hypergonadotropic amenorrhea and premature ovarian failure
13. Clinical manifestations of ovarian toxicity
14. Effects of smoking on fertility from gametogenesis to implantation
15. Oocyte destruction by polycystic aromatic hydrocarbons
16. The effect of intraovarian injection of benzo(a)pyrene on primordialoocyte number and ovarian aryl hydrocarbon [bemzo(a)pyrene] hydroxylase activity
17. Murine strain differences in ovotoxicity following intraovarian injection with benzo(a)pyrene, (+)-(7R,8S)-oxide, (−)-(7R,8R)-dihydrodiol or (+)-(7R,8S)-diol-(9S,10R)-epoxide-2
18. Female germ cell loss from radiation and chemical exposure
19. Antiproliferative agents and drugs used for immunosuppression
20. Cyclophosphamide in the treatment of systemic lupus erythematosus of mice and men
21. Preliminary report on long-term cyclophosphamide therapy in rheumatoid arthritis
22. Cyclophosphamide therapy in connective tissue disease
23. Amenorrhea after immunosuppressive treatment of multiple sclerosis
24. Effect of cyclophosphamide on lipoid nephrosis in the human and on aminonucleoside nephrosis in the rat
25. The problem of oncostatic specificity of cyclophosphamide (NSC - 26271): Studies on reactions that control the alkylating and cytotoxic activity
26. Uber Blutspiegel und Urenausscheidung von Aktiviertem Cyclophosphamid und Seinen Deaktwierungs-produkten Beim Menschen
27. Cyclophosphamide and reproductive function
28. Multiple late complications of therapy with cyclophosphamide, including ovarian destruction
29. Sterility and cyclophosphamide
30. Cyclophosphamide induced ovarian failure
31. The growth of follicles in the rat ovary under the influence of busulphan and endoxan
32. Influence of endoxan on the rat testis
33. Changes in mouse ovaries after prolonged treatment with cyclophosphamide
34. The effects of cyclophosphamide azathioprine and 6-mercaptopurine on oocyte and follicle number in C57 BL/6N mice
35. Effect of cyclophosphamide on oocyte and follicle number in Sprague-Dawley rats, C57BL/6N and DBA/2N Mice
36. The effects of x-irradiation on mammalian oocytes in organ culture
37. The action of ionizing radiations on the mammalian ovary
38. Synthesis of 4-hydroperoxy derivatives of ifosfamide by direct ogonation and preliminary antitumor evaluation in vivo
39. The effect of “activated” cyclophosphamide on rat granulosa cells in vitro
40. Cytotoxic activity relative to 4-hydroexcyclophosphamide and phosphamide mustard concentrations in the plasma of cyclophosphamide-treated rats
41. Low concentrations of “activated” cyclophosphamide inhibit progesterone (PROG) accumulation in long term granulosa cell (GC) cultures
42. Effect of activated cyclophosphamide on human granulosa cell function in vitro
43. DNA as a target in cancer chemotherapy: measurement of macromolecular DNA damage produced in mammalian cells by anticancer agents and carcinogens
44. Effect of cyclophosphamide on the immature rat ovary
45. Cell cycle effects of alkylating agents
46. Inhibition of post implantation development of mouse blastocysts in vitro after cyclophosphamide treat in vivo
47. The effects of cyclophosphamide on alkaline phosphatase activity and on in vitro post-implantation murine blastocyst development
48. Recent progress in teratology - a survey of methods for the study of drug actions during the preimplantation period
49. Investigations on cyclophosphamide treatment during the preimplantation period. I. Differential sensitivity of preimplantation mouse embryos to maternal cyclophosphamide treatment
50. An assessment of the effects of cyclophosphamide of sodium valproate on preimplantation mouse embryos during the fluorescein diacetate test
51. Studies in oogenesis and embryogenesis: Experiences with the dominant lethal test in female mice: effects of alkylating agents and artificial sweeteners on preovulatory oocyte stages
52. Effect of “activated” cyclophosphamide on mouse oocyte in vitro fertilization and cleavage
53. Cell-specific expression of immunoreactive cholesterol side-chain cleavage cytochrome P-450 during follicular development in the rat ovary
54. Immunofluorescent probing of mitochondrial cholesterol side-chain cleavage cytochrome P-450 expressed in differentiating granulosa cells in culture
55. The female reproductive system
56. Intercellular communication between granulosa cells and mouse oocytes: Existence and possible nutritional role during oocyte growth
57. Vinblastine reduces progesterone accumulation by rat granulosa cells in vitro
58. Delay of puberty and inhibition of reproductive processes in the rat by a gonadotropin releasing hormone agonist analogue
59. Multiple inhibitory actions of luteinizing hormone releasing hormone agonist on luteinizing hormone/human chorionic gonadotropin receptor mediated ovarian responses
60. 9-NE1]-luteinizing hormone releasing hormone factor inhibits follicular development in hypophysectomized rats
61. Inhibitory actions of a gonadotropin releasing hormone agonist on ovarian follicle stimulating hormone receptors and adenylate cyclase in vivo
62. Inhibitory effect of long-term treatment with a luteinizing hormone agonist on the pituitary-gonadal axis in male and female rats
63. Stimulation of LH fragments with reduced bioactivity following GnRH agonist administration in women
64. Inhibition of ovarian luteinizing hormone (LH) and follicle stimulating hormone receptor levels with an LH-releasing hormone agonist during the estrus cycle in the rat
65. Ovarian gonadotropin releasing hormone receptors. II. Regulation and effects on ovarian development
66. Relative importance of adenohypophyseal and gonadal sites of inhibitory action of LHRH agonist
67. 9-NEt] luteinizing hormone releasing factor on reproductive processes in the female rat
68. The effect of hypophysectomy on age changes in the ovaries of mice
69. The effect of food restriction and hypophysectomy on numbers of primordial follicles and concentrations of hormones in rats
70. Ovarian morphology in women with anosmia and hypogonadotropic hypogonadism
71. Luteinizing hormone releasing hormone agonist inhibits physiologic ovarian follicular loss in rats: Potential for postponing menopause
72. 3H-thymidine uptake by LHRH agonists: a mechanism of preventing damage by cytotoxic agents
73. LHRH agonist inhibits tritiated thymidine (3HT) incorporation into ovarian DNA in rats: a potential mechanism for preventing damage by cytotoxic agents
74. LHRH agonist partially inhibits tritiated thymidine (3HT) incorporation into testicular DNA: relation to gonadal protection
75. The protection of ovarian follicles from ionizing radiation with the agonist of LHRH ethylamide
76. Equivalence of x-irradiation in vivo or in vitro on mouse oocyte survival
77. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin releasing hormone
78. Protection of germinal epitelium with luteinizing hormone-releasing analogue
79. Absence of testicular protection by a gonadotropin-releasing hormone analogue against cyclophosphamide-induced testicular cytotoxicity in the mouse
80. Potentiation of cisplatinum induced testicular damage in rats by GnRH analogs
81. Potentiation of the gonadotoxicity of Cytoxan in the dog by adjuvant treatment with luteinizing hormone-releasing hormone agonist
82. Effect of treatment of rats with LHRH agonist (Zoladex) on the magnitude of procarbazine and hydroxyurea-induced testicular damage
83. Luteinizing hormone releasing hormone LHRH and its analogs for contraception in women: A review
84. Specific binding of gonadotropin-releasing hormone and an agonist to human corpus luteum homogenates: Characterization properties and luteal phase levels
85. Absence of gonadotropin releasing hormone receptors in human gonadal tissue
86. Clinical aspects of LHRH analogues in gynecology: A review
87. Ablation of folliculogenesis in women by a single dose of gonadotropin-releasing hormone agonist: Significance of time in cycle
88. Absence of LH-RH binding sites in corpora lutea from rhesus monkeys (Macaca mulatta)
89. Studies of a controlled-release microcapsule formulation of an LH-RH agonist (D-Trp-6-LH-RH) in the rhesus monkey menstrual cycle
90. 6-luteinizing hormone releasing hormone in the rhesus monkey (Macaca Mulatta)
91. Inhibition of folliculogenesis in the monkey following early follicular phase administration of an LHRH agonist
92. The effects of chronic administration of LH-RH agonists and antagonists on the menstrual cycle and endometrium of the rhesus monkey
93. Gonadotropin-releasing hormone agonist suppresses ovulation, menses, and endometriosis in monkeys: An individualized, intermittent regimen
94. Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin)
95. Recovery of spermatogenesis in rats treated with nitrofurans
96. D-tryptophan-6-analog of luteinizing hormone releasing hormone as a protective agent against testicular damage caused by cyclophosphamide in baboons
97. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease
98. The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease
99. Hormone and liver function
100. The conservation of fertility by a long-acting gonadotropin releasing hormone analogue in patients treated for Hodgkin's disease
101. Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations
102. Progeny of childhood cancer survivors
103. Pregnancy following nonsurgical donor ovum transfer to a functionally agonadal woman